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Abstract 
 
Epidemiologic and clinicopathologic features, therapeutic strategies and prognosis for acinic 
cell carcinoma of the major and minor salivary glands are critically reviewed. We explore 
histopathologic, histochemical, electron microscopic and immunohistochemical aspects and discuss 
histologic grading, histogenesis, animal models and genetic events. In the context of possible 
diagnostic difficulties the relationship to mammary analogue secretory carcinoma is probed and a 
classification is suggested. Areas of controversy or uncertainty, which may benefit from further 
investigations, are also highlighted. 
 
Keywords: Acinic cell carcinoma; Pathology; Salivary glands; Therapy; Prognosis; Mammary 
analogue secretory carcinoma. 
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Introduction 
 
The International Head and Neck Scientiﬁc Group regarded that a series of articles revisiting 
the major epithelial salivary malignancies in the light of contemporary knowledge, would be of 
interest. In this respect, an article on adenoid cystic carcinoma[1] as well as on  mucoepidermoid 
carcinoma have recently been published[2] and are now followed by the present article on acinic cell 
carcinoma (AcCC). This was deemed appropriate as both mucoepidermoid carcinoma and AcCC are 
characterized by innate acinar differentiation and an often favourable prognosis,[2,3] features 
interesting enough to result in intensive study and accumulating literature. The structure of the present 
article and the principles of our approach are similar to those of the previous.[1,2] We review salivary 
gland AcCC, critically appraising the recent literature and integrating recent findings into the existing 
knowledge base, predicated on extensive clinical experience, epidemiological, clinicopathological, 
imaging and genomic aspects that determine our management decisions and consequent prognosis. 
 
Definition and brief historical survey 
 
The World Health Organisation (WHO) currently defines salivary AcCC as “a malignant 
epithelial neoplasm of salivary glands in which at least some of the neoplastic cells demonstrate serous 
acinar cell differentiation, which is characterized by cytoplasmic zymogen secretory granules. Salivary 
ductal cells are also a component of this neoplasm.”[3] Commitment to the characterisation of the 
secretory granules as zymogen and interpretation of the cells lacking obvious secretory granules as 
ductal cells may be criticized. The definition is, however, useful because emphasizes the presence of a 
structural component other than serous-like acinar cells. 
Godwin et al. traced the earliest cases back to the 1890s,[4] Nasse being generally regarded as 
having described the first case in 1892 as a ‘blue dot tumor’, because of the appearance of what we 
now know are  intracytoplasmic zymogen granules.[5] It is likely that the serous-cell phenotypes and 
apparent circumscription of the tumour accounted for the description of serous cell or acinar adenomas 
in the earlier literature.[6] Buxton et al. probably described the first cases of AcCC with a 
straightforward malignant behavior.[7]  Foote and Frazell are usually credited with the “modern” 
morphological descriptions of the tumor,[8]  but it was oral pathologists who subsequently took the 
lead. Their efforts culminated in 1965 when a group led by Abrams published a detailed 
clinicopathologic study of 77 cases of AcCC of major salivary glands from the archives of the Armed 
Forces Institute of Pathology (AFIP), which defined particular growth patterns and tumour-cell 
types.[9] In the 1970s the publication of the World Health Organization (WHO) histological 
classification of salivary gland tumors[10] and also the seminal volume by Thackray and Lucas 
spearheaded the now discarded term “acinic cell tumor”[11]  (with the suggestion to only use the term 
“carcinoma” if the tumor “happens to metastasize”) and general pathologists with a special interest in 
head and neck entered the field.[12-14] Oral pathologists responded by defining clinicopathologic 
features of AcCC in minor salivary glands,[15,16] revisiting the AFIP archives of 294 cases[17]  and 
aptly presenting the experience in the AFIP atlas.[18]The accumulating clinicopathologic experience 
together with investigative approaches using modalities such as electron microscopy, histochemistry 
and immunohistochemistry substantially increased our understanding of AcCC. There seemed little 
wishing for and AcCC did not feature in reviews of advances in salivary pathology.[19,20] However, 
the notion of AcCCs entirely composed of non-descript cells lacking secretory granules, illustrative per 
se of the inherent difficulties in precisely characterising cells of simple phenotypes, should warrant a 
certain apprehension. This proved well-founded in 2010 when the so-called mammary analogue 
secretory carcinoma (MASC), a low-grade salivary malignancy that is histologically similar to AcCC 
of non-serous acinar cells and harbours the ETV6-NTRK3 translocation, was reported.[21]  
Subsequently Bishop et al. reclassified most non-parotid AcCC of non-serous cells as MASCs.[22] 
Whether MASC is a distinct entity remains to be established, which is discussed below (see ‘Proposed 
classification’), but is a concept that should be considered when the earlier literature is reviewed.  
Whereas most clinicians still associate AcCC to a good prognosis, recent studies increase our 
awareness of the propensity of this tumor for lymphatic invasion and distant metastases, developing in 
a protracted and unpredictable clinical course. Indeed, (late) distant metastases to the lungs, pleura, 
brain, peritoneum, paraaortic, paratracheal, and mediastinal lymph nodes, as well as cutaneous 
metastases, have been described, especially in the de-differentiated subgroup of AcCC, nowadays 
commonly referred to as “acinic cell carcinoma with high grade transformation”.[13,23-25] 
 
Epidemiology 
 
Unfortunately, the highly desirable population based studies provide little information beyond 
incidence and survival.[26-28] Institution-based studies are more detailed, but report limited number 
(up to 35) of cases collected over a long period and treated without standardized protocols, which 
makes statistical evaluation difficult.[29-32] 
In western countries, salivary gland carcinomas (SGCs) account for about 4% of all head and 
neck cancers, approximately 80% occurring in the parotid.[33]  About 1 out of 6 parotid cancers is 
AcCC,[34] which is supported by a nationwide study in Netherlands, where 15% of parotid 
malignancies were AcCC.[26] A recent Surveillance, Epidemiology and End Results (SEER) analysis 
from 1973 to 2009 indicated that AcCC comprises 11% of all salivary gland malignancies, with an 
average annual incidence of 0.13 cases per 100,000 patients per year during the 36 years the study 
encompassed.[28] Incidence trend analysis, stratified for gender and race, indicated a significant annual 
increase (annual percentage change of 1.06%).[28]  Rather than being genuine, this trend is attributable 
to improved and increasingly widely known histopathologic diagnostic criteria. The SEER analysis 
also indicated a higher average annual incidence for females (0.15 cases per 100,000 patients) in 
comparison to males (0.11 cases per 100,000 patients). This correlates with a consistent slight female 
predominance in institutional[35,36] and population based series. The latter report female:male 
incidence ratios ranging from 1.43:1 to 1.57:1.[27,28,37] 
The age distribution of AcCC seems quite even throughout all decades, with one third of 
patients below the age of 40, one third between 40 and 59, and one third above 60 years.[28] This 
corresponds to the findings in a series from the MD Anderson Cancer Center (MDACC).[36]  With a 
median age at diagnosis of 52 years, AcCC tends to occur at a younger age than other SGCs.[27]  
Children are very rarely affected by SGCs, but when they are mucoepidermoid carcinoma is most 
frequently observed, followed by AcCC.[38,39] 
AcCC is predominantly diagnosed in whites (85%) and less frequently in blacks (7%) or other 
racial backgrounds (8%).[28,32] Very little is known regarding risk factors for AcCC. Although 
familial predisposition and previous radiation exposure have been considered, no cases were noted 
among long-term atomic bomb survivors[40] and descriptions of familial occurrence are very sparse. 
[41] One case has been reported in an individual with Cowden syndrome,[42] and there is a recent case 
report of AcCC of the breast developing in a BRAC1 mutation carrier.[43] 
 
Clinical features 
 
In the major salivary glands, the parotid is most commonly affected, the typical clinical 
presentation being a slow-growing swelling. Symptoms are often lacking, which often results in late 
diagnosis. Pain or fixation to surrounding tissues herald poor prognosis. [35] Nodal metastasis is 
extremely uncommon at presentation. In the MDACC series mentioned above, only 12 of 155 patients 
(8%) had nodal disease, even when 75% presented with persistent or recurrent AcCC.[36]  In another 
series from the Memorial Sloan Kettering Cancer Center (MSKCC), 3 out of 35 patients (9%) 
presented with nodal disease; also uncommon in this series were pain (n=5; 13%) and cranial nerve VII 
dysfunction (n=1; 3%).[32] 
AcCC is far less common in minor salivary glands. A population-based report identified 736 
cases of parotid AcCC (91%) compared to only 42 cases (5%) in other major and 35 cases (4%) in 
minor salivary glands.[27] In addition, AcCC of minor salivary glands accounts for about 9% in a 
SEER database.[44] The trend is also a feature of institutional series[36]  and in case reports.[45,46] 
Whether this relates to a generally decreased proportion of serous acinar cells in normal minor salivary 
glands, is unknown. In contrast to other types of minor SGCs, which mainly occur in the palate, [47]  
AcCC mainly occurs in the buccal mucosa and upper lip.[31]  A small minority of AcCC arise in the 
sinonasal area[44,48]  or the larynx,[49]  but these are outside the scope of the present article. 
Bilateral AcCC is highly controversial. While some urge caution or are unconvinced, [50] 
others suggest that AcCC is the most frequently reported bilateral SGC.[51,52] For completeness, non-
salivary AcCC have been described in the lacrimal gland, pancreas and breast. The tumors in the 
pancreas are referred to as acinar cell carcinoma.[43,53]  
 
 
Pre-operative assessment 
 
Surgery is the first and most important step in the management, if technically feasible and if 
there are no medical contraindications. Preoperative assessment of AcCC is similar to that of other 
tumors of the major salivary glands and involves imaging and needling procedures. Since AcCC often 
presents as a swelling, with little to suggest malignancy, pre-operative assessment aims at assessing 
localization, extent, indicators of malignancy, as in the case of parotid AcCC, these factors will 
determine the risk to the facial nerve during surgery. [54] Imaging can be omitted without detriment to 
further management in mobile, circumscribed tumors where localization and extent are clinically 
obvious. It is strongly recommended when a glandular swelling is associated with impaired mobility or 
when involvement of deeper structures/cranial nerves is suspected.[55-58] For AcCC, impaired 
mobility is typically seen in larger tumors or, more frequently, in local recurrences. 
Pending on particular circumstances, pre-operative imaging includes ultrasound (US) (Fig. 1), 
computed tomography (CT), magnetic resonance imaging (MRI) (Fig. 2) and positron emission 
tomography (PET).[54] 
A recent study comparing US and CT indicated that most primary AcCCs show ‘benign’ 
imaging features reconcilable with the often favourable prognosis of the tumor. On US, AcCC 
appeared lobular, rather defined, hypoechoic, heterogeneous and poorly vascularized (Fig.1); on CT, it 
appeared regular and variably defined with limited heterogeneous enhancement.[59] The study 
supported the earlier findings of Suh et al., who described CT qualities of AcCC in relation to 
histopathologic features.[60] 
MRI is superior to CT in assessing parotid, stylomastoid foramen and any facial nerve 
invasion/perineural extension (Fig. 2).[56,57,61,62] It is particularly indicated for patients with 
recurrent or residual AcCC and favored in tertiary centers where these patients are usually referred. As 
an example, 75% of patients treated in MDACC had residual or recurrent disease; for these patients a 
meaningful statement on the feasibility of further treatment without an adequate was judged impossible 
without MRI.[36] 
PET with or without CT should be considered in clinically/radiologically suspected or 
needling-procedure proven, advanced stage, salivary malignancies, to exclude gross, distant disease. 
This is a very uncommon situation in AcCC.[54] PET may be, however, recommended post-
operatively when a histologic diagnosis of AcCC with high grade transformation is established.[63-65] 
The needling procedures are usually ultrasound guided and include fine needle aspiration 
cytology (FNAC) and core biopsy (USCB). FNAC is an integral part of the pre-operative assessment, 
and it has been repeatedly emphasized that the value of FNAC reflects the experience of the operator, 
yield of material and expertise of the pathologist interpreting the aspirate, which in turn are influenced 
by the number of salivary tumors managed in particular institutions. Data on the role of FNAC in 
diagnosing AcCC (Fig. 3a) are limited. Overall sensitivity is low, often due to a false negative 
interpretation of tumoral acinar structures (see ‘Pathology’) as normal parenchyma. Accuracy of 17% 
(2 out of 12)[30] and a specificity of 27% (4 out of 15)[66]  have been reported. Cystic tumours (see 
‘Pathology’) present additional problems, since obtained aspirates may be hypocellular and 
misinterpreted as a benign salivary cyst. Centrally placed nuclei, less demarcated cell borders and lack 
of association with adipocytes may be helpful in distinguishing AcCC with prominent serous acinar 
cell differentiation from normal acini, [18]  and the presence of large nuclei with distinct nucleoli and 
binucleated cells are further alerting features.[67] FNAC diagnosis of AcCCs entirely composed of 
non-descript cells lacking secretory granules is more difficult. The accuracy of FNAC seems higher for 
AcCC with high grade transformation (see ‘Pathology’),[64] but this likely reflects detection of 
obviously malignant cells rather than identification of conventional AcCC. USCB has been less 
explored, but further immunohistochemistry (see below) can be applied to the material thus obtained 
(Fig. 3b); a modest 50% accuracy may be obtained with frozen sections of open biopsies.[66] 
 
Pathology 
 
This remains the gold standard for the diagnosis of AcCC. 
 
Macroscopical appearances 
 
Salivary AcCCs are often rounded, circumscribed and even variously encapsulated 
masses.[18,68] Lobulation can be seen, whereas infiltrative growth into adjacent tissues is uncommon. 
Pending on site, ACCs often range from < 1.0 cm to 4.0 cm. Sizes up to 13.0 cm have been 
reported,[18] possibly reflecting delayed diagnosis or neglected cases. Tumors of minor salivary glands 
are usually smaller due to earlier detection. Upon dissection, AcCCs are rubbery and solid or variably 
cystic (Fig. 4). Solid areas are greyish-white or tan with areas of haemorrhage. Necrosis together with 
multiple, variously separated masses and infiltrative qualities are not uncommon in recurrences.[4,68] 
 
 
Histology 
 
This is outlined in Table 1. The following discussion is based in standard references and 
personal experience. [3,9,11,12,14,15,17,18,68-70] 
On routinely-prepared sections of resection specimens examined at scanning magnification, 
AcCCs are variously solid or cystic growths that appear hematoxyphilic or eosinophilic (Fig. 5), the 
latter influenced by the serous:non-serous cell phenotype ratios and/or proportion of fibrous stroma. 
Although the tumours are usually non-encapsulated and asymmetrical, they are often lobulated and 
variously circumscribed; even a fibrous capsule may be seen. Encapsulated, hematoxyphilic tumours 
would account for Nasse’s ‘blue dot tumor’,[5] and erroneous diagnoses of serous cell or acinar 
adenoma. 
Tumours of minor salivary glands are centred in the submucosa where they are partly 
surrounded by salivary lobules; they may involve main ducts (Fig. 5a). Similarly to mucoepidermoid 
carcinoma,[2] ‘flooding’ of the lamina propria is unusual. Parotid AcCCs are often superficially located 
- hence, partly surrounded by glandular lobes (Figs 5b, c). 
Fig. 5 also allows appreciation of various silhouettes of AcCC. Tumours irregularly 
penetrating salivary lobules, soft tissues or bone, ‘satellites’ invading far ahead of the main growth, 
perineurial invasion and necrosis are not frequent.  
Various patterns of growth can be seen. They include solid, microcystic, follicular, papillary 
(Fig. 6) and cystic (Fig. 5c); and occur alone or in combination.[17,71]  
About a quarter of AcCCs are solid with an easily recognized histology. The tumour 
parenchyma therein is organized in packed aggregates, largely of differentiated, serous-like cells laden 
with hematoxyphilic, secretory granules (Fig. 6a). The solid pattern is characterized by sheets of cells 
separated by thin fibrovascular strands, and thus often appears trabecular to acinar. When small lumina 
are formed between the cells the pattern becomes microcystic (lattice-like). Table 2 compares this 
conventional subtype of AcCC with normal parotid; some of the features are further described below 
(see ‘Histochemistry and electron microscopy’ and ‘Immunohistochemistry’). It is noted that 
occasional intercalated duct-like structures may be irregularly/asymmetrically mixed with serous cell 
aggregates in conventional AcCCs. 
About 77% of AcCCs are non-solid variants composed of varying proportions of non-serous 
cells in microcystic, cystic, follicular and papillary architectural arrangements (Figs 5c, 6b-d), which 
often present diagnostic difficulties for the non-specialist. For instance, follicular AcCC with its 
follicular-like structures, lined by cuboidal or flattened epithelial cells containing colloid-like 
secretion,[71] may resemble thyroid carcinoma; small papillary AcCC could be mistaken as papillary 
cystadenoma. The non-serous cells are traditionally regarded as intercalated duct-like cells. They are 
small, cuboidal with indistinct borders, scant eosinophilic cytoplasm and central, lightly stained nuclei 
with inconspicuous nucleoli (Fig. 7); denser nuclei are associated with follicular arrangements. 
Both serous and non-serous cells may show characteristic cytoplasmic ‘vacuoles’ that 
probably reflect cytoplasmic lumina (see ‘Histochemistry and electron microscopy’ (Figs 6a, 7) and are 
diagnostically useful. They may coalesce in AcCCS composed of non-serous cells, which results in 
true lumina and microcystic areas eventually. 
In our opinion, the presence of ‘clear’ cells in AcCC has been overemphasized. Certainly 
‘pale’ cells are a feature of AcCC (Fig. 8a), but they are not extensive and their cytoplasmic qualities 
are not those of the ‘empty’ appearing clear cells of mucoepidermoid carcinoma.[2] On these grounds, 
purported difficulties in distinguishing ‘clear’ cell AcCC from hyalinizing clear cell carcinoma or 
epithelial-myoepithelial carcinoma do not seem justified. 
Apocrine and mucous phenotypes (Fig. 8), mitoses, microliths[72] and iron uptake/storage 
(Fig. 9) are occasionally seen in AcCC. Iron uptake/storage may be diagnostically useful, but can be 
seen in salivary adenomas as well.[73] Similarly to mucoepidermoid carcinoma,[2] stromal lymphoid 
aggregates/benign lymphopoiesis and cholesterol granulomas are features of AcCC (Fig. 10). The 
former may be conspicuous and is well established - hence, attempts at defining a novel ‘Warthinoid’ 
subtype of AcCC do not seem justified. 
The characterisation ‘dedifferentiated’ or, preferably, ‘AcCC with high grade transformation’ 
is used when a typical low-grade AcCC, primary or metastatic, shows areas resembling high-grade 
adenocarcinoma (Fig. 11) or undifferentiated carcinoma (including small cell carcinoma types). These 
lesions may reflect histologic progression and cannot be identified without areas of typical AcCC 
appearance.[23,25,74] Whenever dedifferentiation or undifferentiated areas are observed, clinical 
outcome is significantly worse, as reflected by the finding of lymph node metastasis or the 
development of distant disease, with about two thirds of patients dying from disease after a median of 
4.3 years.[25] 
Similarly to mucoepidermoid carcinoma,[2] AcCC shows little or no epithelial-mesenchymal 
transdifferentiation (EMT).[75] 
 
Histologic features of prognostic significance and grading  
 
Histologic features of AcCC that may influence prognosis include: size; silhouette/ tumor 
delineation (circumscribed versus infiltrative); stromal lymphoid aggregates/tumor associated 
lymphoid proliferation (TALP); necrosis; mitotic rate determined by examining 10 high-power fields 
(HPFs) in areas of greatest concentration of mitoses; atypical mitoses; nuclear pleomorphism; 
extension beyond the glandular capsule, although this is inapplicable to tumors of non-encapsulated 
minor salivary glands; vascular and perineural invasion; status of resection margins and regional lymph 
nodes; and proliferative index usually determined by immunohistochemistry for the Ki-67 antigen (also 
see ‘Immunohistochemsitry’) (Fig. 12).[30,32] Controversy surrounds the possible significance of 
architectural arrangements. Spiro et al suggested that papillary/cystic patterns are associated with worse 
survival,[12]  but this was not confirmed by others.[13,32,35,71] Overall, especially adverse histologic 
features indicating worse overall/disease-free survival and locoregional control (see ‘Prognosis’ and 
Table 4 therein) are positive resection margins, extracapsular extension, vascular/perineural invasion, 
necrosis, nuclear pleomorphism, high mitotic rate (>2/10 HPFs), atypical mitoses and a Ki-67 index > 
5%.[30,32] Low Ki-67 (< 5%) correlate with TUNEL (terminal deoxynucleotidyl transferase [TdT]- 
mediated dUTP-biotin nick end labeling: identification of DNA breaks in apoptotic cells) positivity and 
a good prognosis.[76,77] 
In contrast with adenoid cystic carcinoma and mucoepidermoid carcinoma, the WHO has not 
suggested a histologic grading system for AcCC.[3]  Features mentioned above would be useful in 
constructing such a system. Recently, a ‘proliferative grading system’ for AcCC has been suggested, 
which distinguishes high- and low-grade tumors based on the presence of an increased mitotic rate (>2 
mitoses/10 HPFs), necrosis and presence of pleomorphic cells in combination with extracapsular 
extension and positive resection margins. Using this system the authors classified 35% of AcCC as 
high-grade. [32] Histologic grading is of significance since high-grade AcCC seems associated with 
advanced-stage disease, higher incidence of distant metastasis and poorer outcome.[27,32,71,78] A 
population-based study analyzed the prognostic effect of histological grade of AcCC and reported that 
patients with low-, moderate or high-grade tumors showed a 20-year survival of 98%, 83%, and 38%, 
respectively.[28]  Grading would also be useful for individualizing treatment; high-grade tumors would 
opt for high intensity management. While additional radiotherapy may be considered for high-grade 
tumors, patients with low-grade tumors would be spared from the morbidity of such intensified 
treatment.[32] 
 
Histochemistry and electron microscopy 
 
Conventional histochemical investigations of AcCC are mainly concerned with demonstrating 
mucosubstances in the cytoplasmic granules of tumor cells. The periodic acid-Schiff (PAS) positive 
reaction of those granules, indicative of the presence of neutral glycoproteins, was firstly reported by 
Godwin et al.[4] and is established. The presence of acidic glycoproteins in AcCC is far less 
appreciated, although the classic study by Abrams et al. noted variable staining of tumor cells with 
aldehyde fuchsin and Alcian Blue (AB), indicative of such glycoproteins.[9]  Fig. 13 illustrates patterns 
of mucosubstance distribution in AcCC. Staining with tannic acid-phosphomolybdic acid-Levanol fast 
cyanine 5RN (TPL), a technique used for demonstrating normal salivary myoepithelial cells, is not 
seen.[79] This would accord with the inconspicuous EMT in AcCC.[75] 
Echevarria’s early electron microscopical investigation reported on the effects of preservation 
in effecting ‘clear’ cell phenotypes and illustrated complex phagosomes in tumor cells.[80] Later 
investigations using material specifically preserved for electron microscopy described variations in the 
electron density of the cytoplasmic granules in tumor cells.[80-82] These granules (Fig. 14) usually 
lack the complex polypartite substructure characterizing the secretory granules of normal salivary 
glands,[83] but preservation nuances should be considered before conclusions are drawn. The presence 
of phagosomes in tumor cells has been confirmed,[82,84] and can be attributed to lysosomal events and 
phagy. This is supported by an electron microscopical cytochemical investigation of AcCC, which 
demonstrated lysosomal enzyme activitity in tumor cells laden with secretory granules.[85]  Recent 
electron microscopical investigations illustrate occasional ‘myoepithelial’ cells at the periphery of 
tumor cell aggregates.[82,84] This should not detract from the notion of inconspicuous EMT in AcCC, 
as limited sampling is an inherent limitation of electron microscopy and the observations are 
inconsistent with the results of TPL-histochemistry[79]  and immunohistochemistry (see below). 
Dardick et al. paid particular attention to the microcystic architectural arrangements in AcCC and 
interpreted them as intercalated duct-like structures.[84]  Chaudhry et al. were able to provide electron 
micrographs of cytoplasmic lumina in tumour cells,[82] which supports their correspondence with the 
histologically seen cytoplasmic vacuoles. Myosin adenosine triphosphatase activity relates to formation 
of lumina in mammalian salivary glands[86] and an electron microscopical cytochemical investigation 
of that enzyme in AcCC would be thus of interest. Secretory granules suggestive of neuroendocrine 
differentiation have been electron microscopically demonstrated in an AcCC of the parotid.[87] 
 
Immunohistochemistry and related modalities 
 
The literature is extensive and as in mucoepidermoid carcinoma, the WHO refrains from 
attempting a meaningful review.[2,3] The present article is not intended as a conventional review of the 
immunohistochemistry of AcCC and the following brief discussion is based on references selected in 
view of the various arguments. 
Studies concerned with comparing expression of various secretory components between 
AcCC and normal salivary glands, reported variable amylase, lactoferrin, secretory piece and proline-
rich protein immunoreactivities in the tumour, whereas lysozyme is rarely expressed.[88] Notably, 
despite histologic similarities between normal serous acini and serous-like tumor cells, amylase is not 
regularly expressed in AcCC. 
The results of immunohistochemically assessing cytoskeleton/cytoplasmic filaments 
correspond with the patterns of tumor differentiation (see ‘Histogenesis and animal models’). 
Cytokeratin (CK) ‘cocktails’ are gradually superseded by staining for individual CKs. The basic CK7 
and acid CK19, which are of low molecular weight and reflect simple glandular phenotypes, are often 
expressed in AcCCs of intercalated duct-like cells in microcystic, cystic, follicular or papillary 
architectural arrangements; based on CK7 staining and analogous to CK7 expression in normal salivary 
gland epithelia, three distinct histogenetic subtypes of AcCC are recognized: acinar differentiation as 
seen in blue dot tumours (CK7-negative), ductal differentiation as seen in papillary-cystic tumours 
(diffuse CK7-positive) and mixed ductulo-acinar (10–66% CK7-positive cells) differentiation.[71] 
Staining for CK7 is not seen in solid AcCCs of serous-like cells.[71] AcCC (both low- and HG 
components) stain with the same intensity using pankeratin antibodies AE1/AE3 and CK18. 
Cytokeratins CK5/6, CK7, and CK19 are expressed in low-grade AcCC, but not in HG components. 
CK14 and CK20 are absent in AcCC.[25] Abundant secretory granules in the latter may, however, 
effect attenuation/displacement of the cytoskeleton and affect detection of immunoreactivities. 
Myofilament-associated smooth muscle actin or calponin immunoreactivities have not been reported in 
AcCC,[89] which accords with the the results of TPL-histochemistry and inconspicuous EMT in 
AcCC.[75,79] Vimentin also seems absent.[90]
 
Novel markers have recently reinforced the particular patterns of differentiation in AcCC. The 
chloride channel DOG1 (Anoctamin-1, described in Gastrointestinal Stromal Tumours – GIST1), 
selectively expressed in the luminal plasmalemma of serous acinar and intercalated ductal cells and the 
transcriptional activator SOX10 expressed in nuclei of those cells, are variously immunolocalized in 
AcCC.[91,92]  Positive DOG1 staining can be an admixture of apical membranous, cytoplasmic and 
complete membranous staining, and would support AcCC versus many differential diagnoses. This 
differential diagnosis includes MASC, but biphasic tumours like e.g. adenoid cystic carcinoma and 
epithelial-myoepithelial carcinoma can also express DOG1, although to a lesser degree and lower 
intensity than AcCC.[91,93] 
Controversy surrounds the expression of plasmalemma-anchored, epithelial membrane antigen 
(MUC1) in AcCC. While Gusterson et al. did not record any immunoreactivity,[94] later studies 
reported regular staining.[95] Of other plasmalemmal molecules, AcCC shows variable membranous 
staining for CD44 and integrin αvβ3.[96] 
Lysosomal events and phagy in AcCC have already been considered (see ‘Histochemistry and 
electron microscopy’). In this vein, an immunohistochemical study demonstrated widespread, 
cytoplasmic and apical expression of CD63, a glycoprotein of lysosomal membranes, in serous-like and 
non-serous tumour cells, respectively (Fig. 15) and around microliths.[97] The findings can be 
attributed to lysosomal processing and/or auto-/heterophagy of secretory material. 
It is generally regarded that S-100 protein is not expressed in AcCC.[98] The significance of 
this rather unpretentious feature is now increasingly appreciated (see ‘Differential diagnosis’ and 
‘Proposed classification’). 
Immunohistochemistry confirmed aberrant neuroendocrine differentiation in few 
AcCCs.[87,99-102] This may result in a paraneoplastic syndrome,[103] but is probably a pathological 
curiosity. 
Except for the S-100 protein immunoreactivities, the above features seem largely academic. 
The following molecular biological aspects can, however, be useful in grading and prognosis.  
Molecules associated with the cell cycle are firstly considered. We have already commented 
on the significance of the Ki67 index (see ‘Histologic features of prognostic significance and grading’). 
The Ki-67 index, an independent prognosticator for all SGCs,[76,104,105] is markedly increased (Ki-
67 index up to 60%) in AcCC with high grade transformation, where high expression of cyclin D1 is 
also seen.[25] In contrast with the Ki-67 index, argyrophilic nucleolar organizer region-associated 
proteins (AgNORs) have not been found of prognostic value in AcCC.[106] Apoptosis assessed by 
immunohistochemistry for bcl-2 protein and TUNEL, seems more pronounced in Stage I AcCC and 
overexpression of p53 (nuclear staining >10%) is low.[107] Recently, the mammalian target of 
rapamycin (mTOR), significant in the homonymous signalling pathway that regulates cell cycle and 
promotes proliferation, has been variously immunolocalized in AcCC.[108,109] 
Growth factor receptors are now considered. A study using a tissue microarray reported 
epidermal growth factor receptor (EGFR, HER-1) immunoreactivity in 30 out of 168 AcCCs (17.9%), 
which varied from weak to strong,[110] whereas a conventional immunohistochemical study reported 
weak staining in 3 out of 6 tumors.[109] Overexpression of epidermal growth factor receptor 2 (HER-
2/neu, ErbB-2) is less common (1 out of 170, 0.59%).[111] In situ hybridization, however, suggests 
that HER-2/neu is overexpressed at the mRNA level in AcCC.[112] In an in vitro situation, targeting 
overexpressed Her-2 with Gefitinib has resulted in cytostasis in one AcCC derived cell line.[113] 
Of proteins involved in DNA damage repair, p53 protein is usually not detected in LG 
components, but strongly expressed (>50%) in the HG areas of AcCC. P63, a p 53 homologue, has 
recently been proposed to differentiate AcCC (no expression) from MEC (nearly always positive). 
[114] The MEC-specific CRTC1-MAML2 gene fusion is another useful biomarker that distinguishes 
MEC from AcCC.[115] 
Little is known about expression of sex hormone receptors in AcCC, which precludes from 
assessing any therapeutic/prognostic correlations. An institutional study reported immunoreactivity for 
androgen receptors in 2 out of 10 tumors.[116] 
 
Cytophotometry and flow cytometry 
 
In contrast with mucoepidermoid carcinoma,[2,117] cytophotometry quantified DNA does not 
correlate with the clinical course of AcCC.[117,118] In addition, prognosis seems similar for tumors 
with diploid or aneuploid DNA assessed by flow cytometry.[106,119] 
 
Differential diagnosis 
 
We have already alluded to potential problems (see ‘Histology’). Diagnosis of solid AcCC 
with largely serous-like cells would not pose significant problems for the aware general pathologist 
with adequate exposure to salivary pathology while in training. AcCC of non-serous cell in various 
architectural arrangements is completely the opposite. Even novices in oral/head and neck pathology 
would experience difficulties and frustration. Detection of cytoplasmic vacuoles would almost be 
diagnostic for the experienced specialist and other clues (eg, hemosiderin pigmentation) would be 
helpful. Standard references offer appropriate advice on the traditional differential diagnosis of AcCC 
from the perspective of trainees/non-specialists.[18,69] and we further comment on particular aspects. 
Largely unicystic, AcCC with stromal lymphoid aggregates may be misinterpreted as lymphoepithelial 
cyst on casual inspection,[60,67] but any invasive growth in the ‘wall’ of the cystic structure and/or 
intraluminal papillations should be alerting. Difficulties in distinguishing follicular and/or papillary 
AcCC from salivary metastases of thyroid carcinomas may have been overemphasized; such 
metastases are rare; when in doubt the characteristic nuclear features of papillary thyroid carcinomas 
(overlapping, ‘empty’ appearance, grooves, pseudoinclusions) should be sought and 
immunohistochemistry (thyroglobulin etc) may not be even necessary. In our opinion, unduly attention 
has been paid to the role of immunohistochemistry for p63 and CK5/6 in differentiating AcCC from 
salivary oncocytoma;[120] recognition of oncocytic features is rather straightforward on hematoxylin 
and eosin stained sections of good quality and solid AcCCs of non-serous, eosinophilic cells are rare. 
Occasionally, however, there are difficulties in distinguishing microcystic and follicular AcCC from 
mucoepidermoid carcinoma with inconspicuous mucous/squamoid cells as both tumors may appear 
variously cystic/papillary with simple, eosinophilic cells and stromal, lymphoid aggregates. In this 
case, immunohistochemistry for p63 is recommended, as staining would be present in 
intermediate/non-descript cells of mucoepidermoid carcinoma and usually absent from 
AcCC.[114,121] 
Currently, the greatest diagnostic challenge is differentiating AcCC from MASC. As MASC is 
histologically similar to microcystic/papillary AcCC of non-serous cells, [21,22,122-128] distinction 
usually relies on special techniques. It has been reported that MASC cells lack PAS-positive secretory 
granules,[122,126] but this is a matter of dispute. In addition, pathologists trained in the present era, 
where diagnostic immunohistochemistry and molecular testing reign, may have difficulties in 
interpreting conventional mucosubstance histochemistry. Immunohistochemistry seems more helpful as 
staining for vimentin, S-100 protein, proteins related to secretory mechanisms (STAT5a and 
mammaglobin) and adipophilin (a component of milk lipid globule membranes) is usually positive in 
MASC, though negative in AcCC.[21,123,127,129] Immunostaining should always be interpreted in 
conjunction with routine histology as S-100 protein and mammaglobin immunoreactivities are features 
of other SGCs.[130,131] In addition, nuclear staining for the transcription factor GATA3 is another 
feature associated with MASC, but not with conventional AcCC.[132] Caution should also be exerted 
as regards staining with adipophilin[126] and cross immunoreactivity with lipid-rich residues of 
lysosomal events/phagy (see ‘Histochemistry and electron microscopy’ and ‘Immunohistochemistry 
and related modalities’) should be considered. A definite diagnosis of MASC can only be established 
via demonstration of the chromosomal t(12;15) (p13;q25) translocation, which results in fusion 
between the ETV6 gene on chromosome 12 (a transcription regulator) and the NTRK3 gene on 
chromosome 15 (a membrane receptor kinase influencing cell proliferation and survival).[126] This 
genetic re-arrangement, usually demonstrated by means of ETV6 fluorescence in situ hybridization 
(FISH),[124,127,128] is not found in other SGCs. [21,133-135] Chiosea et al. detected ETV6 
translocation in so-called ‘zymogen granule poor AcCCs’, but they subsequently re-classified them as 
MASC.[125]  
It should be appreciated that FISH and antibodies for mammaglobin or DOG1 may not be 
available to all pathology laboratories. We therefore recommend that all salivary tumors with a 
histologic appearance of non-serous, microcystic/papillary AcCC are routinely immunostained for S-
100 protein. If staining is negative, a diagnosis of AcCC should be established; if staining is positive 
and in the absence of more specific tests, the pathologist should raise the possibility of MASC and 
explain the situation in his/her report. The nuances in distinction may be academic to clinicians as both 
conventional AcCC and MASC share a similar outcome.[125] 
 
Histogenesis and animal models 
 
Although proliferative capacity lies with all types of salivary glandular cells,[72] the origin of 
AcCC has been traditionally sought among purported, ‘semipluripotential reserve’ or ‘stem’ cells 
located at the acinar-intercalated ductal region of salivary glands; proliferation and abnormal 
cytodifferentiation of those cells would result in AcCC.[7,23,136,137] Chaudhry et al. attributed 
‘pluripotential reserve/stem’ qualities to simple tumor cells with a high nuclear:cytoplasmic ratio and 
few organelles.[82] Overall interpretations of electron microscopical observations[82,84] and the 
immunohistochemical localization of DOG1 and SOX10 in AcCC,[92,94] as discussed above, suggest 
that the histogenesis of AcCC simulates events at the ends of branching rudiments during salivary 
embryogenesis. In this regard we may envisage the histology of AcCC (see above) as a continuum. At 
one end would be AcCC of simple duct-like cells (intercalated duct-like or incompletely differentiated 
acinar) in microcystic or other architectural arrangements, whereas at the other end would be solid 
AcCC of differentiated serous-like cells; AcCC of varying proportions of duct-/serous-like cells 
possibly occupies a middle position and myoepithelial differentiation is not prominent. Interestingly, 
the acinar differentation seems functional as in-vitro tumour cells secrete amylase when stimulated by 
adrenalin.[48,138,139] The features in S1 can be reconciled with this histogenetic model; AcCC may 
spread to involve main ducts and acini emptying into proximal extralobular ducts have been described 
in mammalian salivary glands.[138] 
Little is known about naturally occurring, animal models for the study of human salivary 
tumours. However, 70% of male transgenic (MMTV/v-Ha-ras) mice develop tumours in their parotids, 
which show electron microscopic features and immunohistochemical expression of amylase similar to 
those of AcCC.[140] The model is of interest, but has not enjoyed widespread endorsement and further 
application. Of greater clinical potential appears the deletion of both the Adenomatous Polyposis Coli 
(APC) and Phosphatase and tensin homologue (PTEN) tumor suppressor genes in mice, which results 
in activation of the mTOR pathway and formation of salivary gland tumors resembling human AcCC 
with 100% penetrance; treatment with the rapamycin inhibited mTOR and led to complete regression 
of tumours, which indicates dependence of growth on sustained signaling.[141] The results allow 
pondering whether treatment with mTOR inhibitors may benefit AcCC patients, given 
immunohistochemical confirmation of activated mTOR signaling in human AcCC.[108,109]  
 
 
Genetics 
 
The genetic landscape of AcCC is insufficiently explored. In the Mitelman database of 
Chromosome Aberrations and Gene Fusions in Cancer there are only 11 cases with cytogenetic 
alterations published (http://cgap.nci.nih.gov/Chromosomes/Mitelman). Early investigations showed 
alterations, often loss of heterozygosity, in 84% out of 25 AcCCs frequently altered regions being on 
4p and 17p, followed by 5q and 6p.[142] The only recurrent changes observed are extra copies of 
chromosome 8 and deletions or translocations with breakpoints in 6q13-q24. Terminal 6q-deletions are 
a typical feature of all major subtypes of SGCs.[143]  A single AcCC showed deletions in the tumor 
suppressor CDKN2A and proapoptotic cofactor of p53-encoding PPP1R13B; and mutations in the cell 
growth regulator EP300.[144] Given the possible significance of the PTEN-activated mTOR signaling 
pathway (see ‘Immunohistochemistry and related modalities’ and ‘Histogenesis and animal 
models’),[108,109,141] the sporadic association of AcCC with the effected by germline mutations of 
PTEN, Cowden syndrome (see ‘Epidemiology’)[42] is of interest.The situation regarding the ETV6-
NTRK3 fusion is still evolving (see ‘Differential diagnosis’ and ‘Proposed classification’). 
 
Proposed classification 
 
The academically meritorious discovery of ETV6 re-arrangement in tumors histologically 
similar to microcystic AcCC of non-serous cells and the introduction of the MASC concept (see 
‘Definition and brief historical survey’ and ‘Differential diagnosis’) has excited much 
interest.[21];[22,122-128] There are over 40 related publications in the PubMed data base 
(http://www.ncbi.nlm.nih.gov/pubmed). The histologic similarities and increased availability of ETV6 
FISH prompted institutional re-examination of cases previously diagnosed as AcCC. While non-serous 
tumors of microcystic and papillary architectural arrangements were thus reclassified as MASC, solid 
tumors of serous cells did not harbor the characteristic gene re-arrangement.[22,125,145] Further 
corroboration is desirable, but the results suggest re-classifying salivary tumors with MASC and 
‘serous cell adenocarcinoma’ (an old term aptly describing solid AcCC of serous-like cells) featuring 
as distinct entities. Breast pathologists support distinguishing secretory from acinic cell carcinoma[133] 
and pending rigorous epidemiological testing, MASC and AcCC may show an opposite gender 
distribution (male-to-female ratio 8:2) as compared to AcCC (male-to-female ratio, 
1:1.5).[27,28,125,146] Alternatively, AcCC lacks a bimodal age pattern (see ‘Epidemiology’); it may 
be imprudent playing down histologic and prognostic similarities between AcCC and MASC;[125] a 
particular genetic alteration may not be detected in every tumor, e.g. the MAML2 re-arrangement is 
seen in 50–70 % of mucoepidermoid carcinomas;[2] regular expression of  DOG1 or SOX10 in every 
AcCC would be unrealistic; and high-quality electron microscopical investigations of MASC are 
urgently needed, particularly in view of observations regarding adipophilin immunoreactivity and 
lysosomal events/phagy (see ‘Differential diagnosis’).[97,127] A sensible compromise in keeping with 
current knowledge and arguments for and against re-classification is shown in Table 3. The approach, 
based on the continuum discussed under ‘Histogenesis and animal models’, suggests a family of tumors 
rather than distinct entities; is centered on the established term AcCC, though in the modified form of 
‘acinic-intercalated ductal carcinoma’ to smooth away the apprehensive notion of AcCCs largely 
composed of cells lacking obvious secretory granules (see ‘Definition and brief historical survey’); and 
would be more palatable to clinicians concerned about intricacies of histologic classifications. 
 
Management 
 
Surgery: the primary tumor 
 
As AcCCs are often anatomically accessible tumors and patients do not show distant 
metastases at presentation, the treatment of choice would be complete resection aiming at achieving 
free margins, thereby avoiding post-operative morbidity.[35,54] AcCC may be, however, initially 
underestimated, as indicated by the high number of redo-cases in a recent study.[36]  
Surgery alone will likely be curative for low-grade AcCC. The extent of the operation should 
parallel the loco-regional anatomical extent of the tumor as influenced by the site of origin. Although 
superficial parotidectomy often effects complete removal, more extended, conservative parotidectomy 
is indicated if the deep lobe is involved. A pre-operatively functioning facial nerve can be preserved 
without loss of oncologic control, even if there would be no margin between tumor and nerve, and any 
microscopic, residual disease seems treatable with postoperative radiotherapy.[54] A more aggressive, 
initial approach would be required for locally advanced AcCCs, especially pre-operatively known high-
grade tumors in risk of positive margins, bone/nerve invasion and nodal metastases. A pre-operatively 
paralyzed or grossly invaded/surrounded facial nerve should be resected and reconstructed with an 
interposition graft from the greater auricular or sural nerve. Advanced cases may also require resection 
of skin, posterior mandible/masseter or lateral temporal bone, followed by a free flap reconstruction. In 
AcCC of minor salivary glands, local anatomy will dictate the best surgical approach.[47]  
 
Surgery: the neck 
 
Elective ND in patients with AcCC is usually not recommended because of a relatively low 
incidence of regional lymph node metastasis (10%). The MDACC study, however, observing that 
addition of an ND to the surgical strategy decreases the rate of regional recurrences, suggests that 
patients with large tumor volume or tumors with high-grade features in the pre-operative biopsy would 
likely benefit from elective ND of levels II, III and IV.[36]  
Clinically positive cervical lymph nodes at presentation are an adverse prognosticator 
necessitating therapeutic ND as part of the surgical approach and should raise suspicion of an AcCC 
with HG transformation. 
 
Radiotherapy 
 
Low grade, low stage (I and II) and adequately resected AcCCs are not considered for 
radiotherapy, as their prognosis is excellent with surgery alone.[54,147] This is supported by a recent 
SEER analysis specifically assessing any oncologic benefits of additional radiotherapy.[148] The study 
did not demonstrate an effect of post-operative radiotherapy on stage I and II, low-grade  AcCC; no 
disease-specific deaths were recorded in 50 stage I, low-grade tumors treated with surgery alone. 
Criteria for additional radiotherapy do not differ from those for other SGCs[54] and include 
salvage surgery for recurrent disease; advanced T-classification (T3/T4); positive surgical margins; 
pathologically positive, cervical lymph nodes; perineural invasion; and high-grade/highly proliferative 
tumors.[28,32,36] Patients with prognostically worse AcCC selected to undergo post-operative 
radiotherapy through application of those criteria, doubled their chance of staying disease-free when 
thus treated (HR of 2, p=0.04) in multivariate analysis).  
Conversely, the SEER analysis undertaken by Biron et al. concludes that ‘radiotherapy 
probably is not effective in AcCC’; the study even suggests and that after multivariate correction for 
stage and grade, radiotherapy implied a death hazard ratio of 2.[44] Caution should be, however, 
exerted as it is imprudent to retrospectively assess the value of a ‘treatment’. It is noted that the SEER 
analysis does not correct for involved resection margins or initially inadequate treatment, which 
account for a substantial part of AcCC patients[36] and would probably end up being radiated. Missing 
data in the variables corrected for, are further weakening the conclusions; for instance, although the 
analysis spanned from 1973 to 2009, precise TNM classification had only been obtained for patients 
from 2000 to 2005.[44] In other words, even after corrected “roughly” for stage and grade, significant 
selection and information bias still is likely present in the retrospective SEER data, resulting from the 
reality that hard-to-capture prognostic factors have usually been incorporated in a clinical decision to 
add radiotherapy to the treatment of early stage AcCC that worries the treating oncologist. 
 
Chemotherapy 
 
Little is known regarding chemotherapy in AcCC. The potential value of mTOR inhibitors has 
already been mentioned (see ‘Histogenesis and animal models’), but no specific chemotherapeutic 
agents have been currently approved. Nevertheless, an observed distant metastasis rate of 1 in 5 (most 
commonly in the lungs) indicates the need for developing such treatment.[36] 
 
 
Prognosis 
 
Endorsing the outlined therapeutic strategies (see ‘Management’), AcCC is generally 
considered to have the best survival rate among SGCs, although the subgroup with high-grade 
tgansformation has a poorer prognosis. [28];[27,149,150] AcCC is by no means an innocent tumor. 
Earlier studies reported that the cure rate decreased from 76-89% at 5 years to 55% at 15 years and 
56% at 20 years,[151] similar trends being noted by others.[12,13]The evidence suggests a protracted 
clinical course with recurrences occurring years or even decades after initial diagnosis and treatment 
(mean time to recurrence, 92 months).[32,35,66] Clearly, this can be an aggressive tumour that should 
be treated accordingly and appropriate initial treatment would thus obviously affect prognosis. Mere 
enucleation is totally inadequate[12,152]  and this has been recently corroborated by multivariate 
analysis.[36] The effects of selectively applied post-operative radiotherapy have been discussed above 
(see ‘Management’).[54,147,153] A recent institutional study indicates a median survival of 28.5 years, 
with only 13 out of 155 patients (8.4%) dying of their disease (mean time to death from disease, 3.8 
years; range, 0.7-11.2 years).[36] Selection/referral bias obviously affects institutional results as large 
tertiary/referral centers a usually end with prognostically worse cases and a higher proportion of 
patients with either residual or recurrent disease after suboptimal initial treatment. Nevertheless, better 
results are now being reported. Recent population-based studies indicate overall 5-, 10- and 20-year 
survival of 97%, 94% and 90%, respectively; survival dropped to 22% in patients with distant 
metastasis.[28]  
Prognostic factors considered as significant are shown in Table 4. They  include age;[36] 
pain;[35] gender, AcCC being probably the sole SGC where this appears significant;[28,36] race, with 
coloured individuals having a worse outcome;[28] previous inadequate treatment;[36] extent of disease 
(advanced T classification, invasion of tumor beyond glandular capsule,  advanced N 
classification);[13,28,32,35,36,44]and especially invasion of the skull base.[154] In a series from the 
Mayo clinic, lateral skull base invasion, mainly direct extension of tumor through the stylomastoid 
foramen, occurred in 1 of 10 patients, in 80% of these following local recurrence.[154] Of note, 
following skull base recurrences, also low grade AcCC had a fatal outcome, and only one in two 
patients with this feature made it through the next two years.[154] 
 Invasion of the anterior skull base is uncommon and typically associated with the rare 
sinonasal AcCC. Anterior skull base invasion is infrequently seen, typically in the rarely occurring 
sinonasal AcCC. However, sinonasal origin as such does not seem to carry a worse prognosis, as 
evidenced from the 18 cases in the SEER database that were matched to major salivary gland 
AcCC.[155] A general idea of the effect of UICC/AJCC stage on outcome in the largest series reported 
to date is that Stage I tumors carry a 93.5% 20 years DSS, Stage II tumors a 98% 20 years DSS, Stage 
III tumors and Stage IV tumors a 64% 20 years DSS.[44] Disease specific deaths are not uncommon in 
the course of AcCC; In a recent series, 76.9% of those were attributable to distant metastases.[32] 
Of the factors considered above, the MDACC multivariate analysis regards the following 
factors as influencing overall and disease-free survival in AcCC: gender, inadequate previous treatment 
(these patients have a significantly higher chance of succumbing to disease and a hazard Ratio of 
recurrence twice as high as that of advanced vs low stage disease), extent of disease (T-classification, 
UICC/AJCC stage), positive resection margins and age at diagnosis.[36] With the exception of gender, 
these factors had already been identified and confirmed in other studies dealing with all types of 
SGCs.[26,156,157] Gender did not feature as a significant prognostic factor in the SEER analysis of 
Biron et al.[44] In the latter analysis, the factors remaining in multivariate analysis were advanced 
stage (HR 2), minor salivary gland subsite (HR 3) and HG (HR 3.3 for grade III and 8.1 for grade IV). 
 
Epilogue 
 
Our perception of salivary AcCC has been repeatedly modified over the 12 decades since its 
description. Successes include the introduction of modern imaging modalities in the assessment of 
patients; application of various morphological methodologies to characterize cellular 
phenotypes/events suggestive of distorted embryonic development; and multivariate analyses of 
population-based datasets/institution-based series indicative of factors influencing prognosis, 
management and outcome. In addition molecular methodologies introduced the concept of MASC and 
prompted further thinking and research. Uncertainties, however, remain. Links between particular 
genetic alterations and cellular phenotypes reflecting abnormal events at the ends of branching salivary 
rudiments should be explored; the role of the S-100 protein in salivary pathobiology should be 
clarified; and high-grade transformation and patterns of nodal metastasis should be precisely 
characterized. Prospects are good, but would require continuous research efforts in the hope that non-
invasive therapies and gene manipulation may become available in future. 
Figure legends 
 
Note. Zooming on the electronic format of the pictures would allow appreciation of detail difficult to 
be seen on print. Unless otherwise specified, the photomicrographs are from sections stained with 
hematoxylin and eosin. 
 
Figure 1. US image of a parotid AcCC (asterisk). Note the homogeneous aspect and the well 
demarcated borders of the tumor. 
Figure 2. Axial T2-weighted MR image of a deep-lobe parotid AcCC (arrow). T2 hyperintensity as 
seen in pleomorphic adenoma, regular borders. 
Figure 3. Aspirate showing aggregates of tumor cells stained with Giemsa (a). Tubulo-acini of tumor 
cells immunohistochemically stained for DOG1 (b). 
Figure 4. The cut surface of a nodular ACC shows variegated appearance of haemorrhagic patches and 
tan or grey, solid areas (a). Another nodular ACC showing variously cystic cut surface (b). 
Figure 5. Scanned histological section of AcCC (T) of the palate; the asymmetrical, lobulated, largely 
solid and hematoxyphilic (purplish) tumour appears stemming from a main duct opening onto surface 
epithelium (E) (rectangled area); and expands the space between lamina propia (asterisk), skeletal 
muscle (M), palatine glands (G) and tonsil (Ton), but does not extend therein  (a). Asymmetrical, 
lobulated AcCC (T) partly centred on superficial parotid (P); though largely solid, the tumour appears 
less hematoxyphilic than that in (a) because of increased, eosinophilic (pink) fibrous stroma (asterisk) 
(b). Largely cystic AcCC (T) of the parotid (P), which appears less defined than that in (b); the variably 
sized cysts contain variously inspissated, eosinophilic or amphophilic, secretory material. 
Figure 6.Solid growth pattern of serous-like, tumour cells in acinous arrangements; note the 
subplasmalemmal, dense nuclei (arrowhead) and hematoxyphilic cytoplasm with vacuoles (arrows); 
interstitial stroma is minimal (a). Microcystic growth pattern; the arrowheads outline a large aggregate 
of non-serous tumour cells surrounding multiple, small, variably rigid lumina containing eosinophilic 
secretion (L); comparison with (a) allows appreciation of differences in size, cytoplasmic hue and 
nuclear position/chromatin pattern between serous and non-serous tumour cells (b). Follicular growth 
pattern; small luminal structures, often rigid and lined by non-serous cells, contain amphophilic, 
secretory material with peripheral bubbling as in thyroid follicles (c). Papillary growth pattern; 
papillations/tufts of non-serous cells are supported by hyperaemic cores (d). 
Figure 7 Cytoplasmic vacuoles (arrows) of non-serous cells. Compare with Fig. 6a. 
Figure 8. Rounded collections of pale cells showing faintly hematoxyphilic, fine granules in a clear 
cytoplasm (a). Apocrine features of adluminal columnar cells; they show eosinophilic cytoplasm and 
intraluminally bulging apex (arrowhead); lymphocytes and extravasated erythrocytes are present in the 
lumen (b). Mucous cells with subplasmalemmal nuclei and bubbly haematoxyphilic cytoplasm 
(arrowheads) in an aggregate largely composed of non-serous tumor cells and variably collapsed small 
lumina (c). 
Figure 9. Collections of heavily pigmented/haemosiderin laden tumour cells (arrowheads) in an AcCC 
of the parotid; a nerve fascicle (N) is seen between the pushing tumour and normal gland (a). Perls 
special staining allows better appreciation of the extent of intracellular haemosiderin in an AcCC with 
papillary growth pattern (b). 
Figure 10. Benign lymphopoiesis (asterisk). Tumour (T). 
Figure 11. Metastasis in a cervical lymph node. While much of the tumour consists of conventional 
AcCC (asterisk), dedifferentiation/high-grade transformation to salivary duct carcinoma with ‘Roman 
bridging’ is seen (arrowhead). A reniform germinal centre is at the left of the picture. 
Figure 12. Peripheral part of an AcCC of the palate (a); adjacent section immunostained for Ki67 
reveals the high proliferative activity of the tumor cells (b). 
Figure 13.  AcCC stained with Alcian Blue at pH 2.5 followed by periodic acid-Schiff. A serous-like 
cell contains neutral and acidic secretory glycoproteins packed in granules staining royal blue (arrow). 
Note the similarly stained glycocalyx of a cytoplasmic vacuole in a non-serous cell (arrowhead). 
Figure 14. Electron micrograph of serous-like cell in AcCC fixed in glutaraldehyde/osmium tetroxide 
and stained with uranyl acetate and lead citrate. Variously dense secretory granules are at the left part 
of the rounded nucleus. Mitochondria and rough endoplasmic reticulum are at the right part. The arrow 
indicates a phagosome. Golgi complex (G.). 
Figure 15. CD63 immunoreactivity in AcCC. Serous-like tumour cells show strong, granular, 
cytoplasmic staining around vacuoles (a); non-serous cells surrounding lumina (L), show strong 
staining of the apical cytoplasm (b). 
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